These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2601 related items for PubMed ID: 24157696

  • 1. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 2013 Oct 25; 62(RR-09):1-12. PubMed ID: 24157696
    [Abstract] [Full Text] [Related]

  • 2. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls.
    Kakkar AK, Dahiya N.
    Tuberculosis (Edinb); 2014 Jul 25; 94(4):357-62. PubMed ID: 24841672
    [Abstract] [Full Text] [Related]

  • 3. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV, Estrada SJ.
    Pharmacotherapy; 2014 Nov 25; 34(11):1187-97. PubMed ID: 25203970
    [Abstract] [Full Text] [Related]

  • 4. ▼Bedaquiline for multidrug-resistant tuberculosis.
    Drug Ther Bull; 2014 Nov 25; 52(11):129-32. PubMed ID: 25395481
    [Abstract] [Full Text] [Related]

  • 5. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, Chuchottaworn C, Vasilyeva I, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, Van Baelen B, van Heeswijk RP, Dannemann B, TMC207-C209 Study Group.
    Eur Respir J; 2016 Feb 25; 47(2):564-74. PubMed ID: 26647431
    [Abstract] [Full Text] [Related]

  • 6. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
    API Consensus Expert Committee.
    J Assoc Physicians India; 2006 Mar 25; 54():219-34. PubMed ID: 16800350
    [Abstract] [Full Text] [Related]

  • 7. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
    Chahine EB, Karaoui LR, Mansour H.
    Ann Pharmacother; 2014 Jan 25; 48(1):107-15. PubMed ID: 24259600
    [Abstract] [Full Text] [Related]

  • 8. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.
    Nguyen TV, Cao TB, Akkerman OW, Tiberi S, Vu DH, Alffenaar JW.
    Expert Rev Clin Pharmacol; 2016 Aug 25; 9(8):1025-37. PubMed ID: 27322153
    [Abstract] [Full Text] [Related]

  • 9. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
    Achar J, Hewison C, Cavalheiro AP, Skrahina A, Cajazeiro J, Nargiza P, Herboczek K, Rajabov AS, Hughes J, Ferlazzo G, Seddon JA, du Cros P.
    Emerg Infect Dis; 2017 Oct 25; 23(10):1711-3. PubMed ID: 28758889
    [Abstract] [Full Text] [Related]

  • 10. Multidrug-resistant tuberculosis and culture conversion with bedaquiline.
    Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RP, Dannemann B, TMC207-C208 Study Group.
    N Engl J Med; 2014 Aug 21; 371(8):723-32. PubMed ID: 25140958
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M, Mok J, Kim DK, Shim TS, Koh WJ, Jeon D, Lee T, Lee SH, Kim JS, Park JS, Lee JY, Kim SY, Lee JH, Jo KW, Jhun BW, Kang YA, Ahn JH, Kim CK, Shin S, Song T, Shin SJ, Kim YR, Ahn H, Hahn S, Won HJ, Jang JY, Cho SN, Yim JJ.
    Trials; 2019 Jan 16; 20(1):57. PubMed ID: 30651149
    [Abstract] [Full Text] [Related]

  • 13. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Cevik M, Thompson LC, Upton C, Rolla VC, Malahleha M, Mmbaga B, Ngubane N, Abu Bakar Z, Rassool M, Variava E, Dawson R, Staples S, Lalloo U, Louw C, Conradie F, Eristavi M, Samoilova A, Skornyakov SN, Ntinginya NE, Haraka F, Praygod G, Mayanja-Kizza H, Caoili J, Balanag V, Dalcolmo MP, McHugh T, Hunt R, Solanki P, Bateson A, Crook AM, Fabiane S, Timm J, Sun E, Spigelman M, Sloan DJ, Gillespie SH, SimpliciTB Consortium.
    Lancet Infect Dis; 2024 Sep 16; 24(9):1003-1014. PubMed ID: 38768617
    [Abstract] [Full Text] [Related]

  • 14. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
    Guglielmetti L, Le Dû D, Jachym M, Henry B, Martin D, Caumes E, Veziris N, Métivier N, Robert J, MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort.
    Clin Infect Dis; 2015 Jan 15; 60(2):188-94. PubMed ID: 25320286
    [Abstract] [Full Text] [Related]

  • 15. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
    Schnippel K, Firnhaber C, Conradie F, Ndjeka N, Sinanovic E.
    Appl Health Econ Health Policy; 2018 Feb 15; 16(1):43-54. PubMed ID: 28980217
    [Abstract] [Full Text] [Related]

  • 16. Bedaquiline for the treatment of pulmonary, multidrug-resistant tuberculosis in adults.
    Gras J.
    Drugs Today (Barc); 2013 Jun 15; 49(6):353-61. PubMed ID: 23807939
    [Abstract] [Full Text] [Related]

  • 17. TMC207 becomes bedaquiline, a new anti-TB drug.
    Palomino JC, Martin A.
    Future Microbiol; 2013 Sep 15; 8(9):1071-80. PubMed ID: 24020736
    [Abstract] [Full Text] [Related]

  • 18. Quabodepistat in combination with delamanid and bedaquiline in participants with drug-susceptible pulmonary tuberculosis: protocol for a multicenter, phase 2b/c, open-label, randomized, dose-finding trial to evaluate safety and efficacy.
    Dawson R, Diacon AH, Takuva S, Liu Y, Zheng B, Karwe V, Hafkin J.
    Trials; 2024 Jan 19; 25(1):70. PubMed ID: 38243296
    [Abstract] [Full Text] [Related]

  • 19. Bedaquiline-containing regimens in patients with pulmonary multidrug-resistant tuberculosis in China: focus on the safety.
    Gao JT, Du J, Wu GH, Pei Y, Gao MQ, Martinez L, Fan L, Chen W, Xie L, Chen Y, Wang H, Jin L, Li GB, Zong PL, Xiong Y, Wu QH, Li MW, Yan XF, Miao YF, Cai QS, Li XJ, Bai DP, Geng SJ, Yang GL, Tang PJ, Zeng Y, Chen XH, Li TX, Cai C, Zhou Y, Zhuo M, Wang JY, Guan WL, Xu L, Shi JC, Shu W, Cheng LL, Teng F, Ning YJ, Xie SH, Sun YX, Zhang LJ, Liu YH.
    Infect Dis Poverty; 2021 Mar 19; 10(1):32. PubMed ID: 33736710
    [Abstract] [Full Text] [Related]

  • 20. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK, Kim JH, Kang H, Cho JS, Smego RA.
    Int J Infect Dis; 2009 Mar 19; 13(2):170-5. PubMed ID: 18768342
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 131.